Jones, R. and DeSantis, M. (2013) Access to targeted therapies in renal cell cancer. Seminars in Oncology, 40(4), pp. 521-528. (doi: 10.1053/j.seminoncol.2013.05.012)
Full text not currently available from Enlighten.
Abstract
There is limited access to targeted therapies for renal cancer in many parts of the western world. This is driven by reimbursement rather than regulatory issues. Indeed, only a small fraction of the global population benefits from unlimited reimbursement of targeted therapies. Dedicated bodies, such as the UK National Institute for Clinical Excellence, assess agents on their cost-effectiveness as well as their efficacy. The results have been disappointing for patients, with the majority of agents being rejected for reimbursement. Despite this trend, there is a general appetite to address cost and value in many part of the world. This article gives a current overview of this rapidly changing field.
Item Type: | Articles |
---|---|
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | Jones, Professor Robert |
Authors: | Jones, R., and DeSantis, M. |
College/School: | College of Medical Veterinary and Life Sciences > School of Cancer Sciences |
Journal Name: | Seminars in Oncology |
Publisher: | Elsevier |
ISSN: | 0093-7754 |
ISSN (Online): | 1532-8708 |
Related URLs: |
University Staff: Request a correction | Enlighten Editors: Update this record